| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| ln Vivo |
An antagonist of NMDA receptors is D-AP5. Long-term potentiation (LTP) and spatial learning are both adversely affected in vivo in parallel dose-dependent ways by chronic intracerebroventricular D-AP5 infusion. Brain concentrations of D-AP5 do not result in any detectable sensory impairment when spatial learning is prevented [2]. During the trial, a progressive decrease in swimming speed was linked to the infusion of D-AP5. When D-AP5-affected animals are unable to learn, they experience sensorimotor abnormalities in spatial tasks that get worse over time. The delayed-match-place protocol of the water maze revealed delay-dependent spatial memory deficits in rats treated with D-AP5 [3].
|
|---|---|
| References |
[1]. R H Evans, et al. The effects of a series of omega-phosphonic alpha-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations. Br J Pharmacol. 1982 Jan;75(1):65-75.
[2]. Davis S, et al. The NMDA receptor antagonist D-2-amino-5-phosphonopentanoate (D-AP5) impairs spatial learning and LTP in vivo at intracerebral concentrations comparable to those that block LTP in vitro. J Neurosci. 1992 Jan;12(1):21-34. [3]. Morris RG, et al. N-methyl-d-aspartate receptors, learning and memory: chronic intraventricular infusion of the NMDA receptor antagonist d-AP5 interacts directly with the neural mechanisms of spatial learning. Eur J Neurosci. 2013 Mar;37(5):700-17 |
| Molecular Formula |
C5H10NO5P-2
|
|---|---|
| Molecular Weight |
195.1104
|
| CAS # |
79055-68-8
|
| Related CAS # |
DL-AP5;76326-31-3;L-AP5;79055-67-7
|
| SMILES |
N[C@H](CCCP(O)(O)=O)C(O)=O
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~27.78 mg/mL (~140.92 mM)
DMSO :< 1 mg/mL Ethanol :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (507.28 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1253 mL | 25.6266 mL | 51.2531 mL | |
| 5 mM | 1.0251 mL | 5.1253 mL | 10.2506 mL | |
| 10 mM | 0.5125 mL | 2.5627 mL | 5.1253 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA